Recombinant CCR4 (Mogamulizumab Biosimilar) antibody

Catalog No. ABIN7072382

The Rabbit Chimeric anti-CCR4 (Mogamulizumab Biosimilar) antibody has been validated for Dep. It is suitable to detect CCR4 (Mogamulizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant CCR4 (Mogamulizumab Biosimilar) antibody (ABIN7072382)

Target: CCR4 (Mogamulizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Chimeric

Conjugate: This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated

Application: Depletion (Dep)

Clone: KW-0761

Product Details anti-CCR4 (Mogamulizumab Biosimilar) Antibody

Purpose: Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa

Specificity: This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogen: This antibody was prepared by humanization of a mouse anti-CCR4 mAb.

Isotype: IgG kappa

Application Details

Application Notes: The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.

Comment:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for CCR4 (Mogamulizumab Biosimilar)

Target: CCR4 (Mogamulizumab Biosimilar)

Target Type: Biosimilar

Background: CD194, CKR-4, CCR-4, CCR4, K5-5

UniProt: P51679